In this "real-life" retrospective study, we assessed outcome after a "personalized" treatment strategy for patients with acute myeloid leukemia (AML) in a tertiary care center. Our strategy consisted of induction therapy adjusted to age, comorbidities and molecular abnormalities, as well as allogeneic stem cell transplantation (allo-SCT) in first complete remission (CR1), whenever possible, for patients with European Leukemia Net 2017 (ELN) intermediate or high-risk patients. Allo-SCT was followed by post-transplant maintenance consisting of 5-azacytidine (AZA) for most patients, or sorafenib for patients with FLT-3 ITD. We included 99 consecutive patients (65% male). The median age at diagnosis was 49 years (range, 18-88) with 28 patients older than 60. Karyotype was normal in 59 patients. Molecular analysis revealed core binding factor (CBF) mutation in 13 patients (13%), NPM1 mutation in 26 patients (26%), FLT3-ITD and FLT3-TKD mutation in 15 (15%) and 1 (1%) patient, respectively. According to the ELN 2017 classification, 24, 48 and 27 patients belonged to the low, intermediate and high-risk groups, respectively.
Patients aged <60 received mainly Idarubicin/Cytarabine induction regimen (sorafenib was added in 2 patients). Patients with CBF AML received Fludarabine/Cytarabine/ Idarubicine (FLAG-Ida) regimen (Gemtuzumab Ozogamicin GO was only added in 1 patient). The majority of the remaining older patients (age ³60) received AZA. Death during induction occurred in 7% of cases, being 6% for patients <60 and 11% for patients above 60. The overall CR rate was 76%, with 6 patients requiring a second induction to achieve CR1. In patients aged <60 and ³60 year-old, the CR1 rates were 82% and 61%, respectively. Allo-SCT was performed in CR1 in 26 patients belonging to the ELN 2017 intermediate and adverse risk groups, 5 of them were aged > 60. Of those 26 transplanted patients, 24 received post-allo-SCT maintenance consisting of AZA in 18 patients (69%) or sorafenib in 6 patients (23%). Allo-SCT was performed in 20 additional patients at time of relapsed and/or refractory disease, with 14 of them receiving post-transplant maintenance.
The median follow-up for alive patients was 35 months. For the whole cohort, the 3-year overall survival (OS) was 54%. In patients aged <60 and ³60, the 3-year OS was 63% and 31% respectively (p=0.002). The 3-year OS were 68%, 60% and 27% in ELN favorable, intermediate and adverse risk groups respectively (p=0.02). In patients who achieved CR after induction, the 3-year leukemia free survival (LFS) was 54% for the whole cohort (57% for patients <60 and 45% for patients ³60, p=0.71), with a 3-year LFS of 58%, 69% and 21% in ELN favorable, intermediate and adverse risk groups respectively (p=0.009). For 41 patients aged less than 60 with ELN intermediate or adverse risk group, the 3 year OS and LFS were 89% and 68% for the 21 patients who underwent allo-SCT in CR1 compared to 37% and 34% for 20 patients who were not transplanted in CR1 (p=0.003 and 0.011, respectively).
These results indicate an improved outcome for AML patients who receive a treatment strategy tailored to age, comorbidities, and disease risk with an overall 76% CR rate and a relatively low rate of mortality during induction (7%). The use of allo-SCT in CR1 followed by post-transplant maintenance significantly improved outcome of young patients (<60) with ELN intermediate or high-risk groups with a 3-year LFS for the ELN intermediate group (69%) likely exceeding that of the ELN favorable group (58%). Results of patients with the ELN favorable group could have been improved with a more systematic use of low dose GO for patients with CBF as well as a more frequent use of allo-SCT in CR1 for patients who remain MRD positive.
No relevant conflicts of interest to declare.
This feature is available to Subscribers Only
Sign In or Create an Account Close Modal